Contrasting Roles of the Galectin-3 in the Schizophrenia Onset, Clinical Presentation, and Somatic Comorbidity

Author(s): Milica M. Borovcanin*, Gordana D. Radosavljevic, Jelena Pantic, Jelena Milovanovic, Natasa R. Mijailovic, Aleksandar N. Arsenijevic, Nebojsa N. Arsenijevic

Journal Name: Current Topics in Medicinal Chemistry

Volume 21 , Issue 16 , 2021

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


The role of the Galectin-3 (Gal-3) has already been explored in various somatic diseases, considering its engagement in infection, acute and chronic inflammation, and autoimmunity. Additionally, it has been recognized that Gal-3 is included in neuroinflammation and neurodegeneration, so we presented the possibility for its involvement in neuroprogression in schizophrenia. Gal-3 possibly participates in the early life programming of schizophrenia, also in the specific response to viral infections as a “second hit” later in life, and as a part of a unique systemic somatic dysfunction leading to the specific mental changes. In this review, we would like to put all these previous observations of Gal-3 properties in the context of schizophrenia onset, clinical symptoms presentation, frequent somatic comorbid states, and future options for Gal-3 centered treatment in schizophrenia.

Keywords: Cognition, Comorbidity, Galectin-3, Neuroinflammation, Neurodegeneration, Psychosis, Schizophrenia.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 02 July, 2021
Page: [1471 - 1487]
Pages: 17
DOI: 10.2174/1568026621666210611162420
Price: $65

Article Metrics

PDF: 209